MEDIA

Our #DNA gene transfer technology is being studied in pivotal Phase II trials in #MetastaticMelanoma. Recent results have demonstrated a local #Immune response as either a #Monotherapy or a #CombinationTreatment approach. Learn more here: https://bit.ly/3jhrukO

#DYK most solid tumors treated with anti-PD-1/PD-L1 therapies do not respond to treatment? This is one of the greatest challenges in #Oncology today. Our Phase II results are pacing the way for the growth of our #ImmunoOncology #Pipeline. Learn more: http://bit.ly/3zS0Y7D

This July, join us in recognizing #UVSafetyAwarenessMonth by taking the right precautions to enjoy the sun & outdoors this #summer while protecting yourself to #PreventCancer. Learn more about ways you can minimize the risk that comes with sun exposure: http://bit.ly/3h4RhtQ

We are pleased to announce that we have entered into a collaboration agreement with @Merck for a pivotal global #Phase3 study, KEYNOTE-687 for late-stage #MetastaticMelanoma. Learn more here: https://bit.ly/3dLpXjp